Step 1 topics → Musculoskeletal, Skin, and Connective Tissue → Basal Cell and Squamous Cell Carcinoma

Basal Cell and Squamous Cell Carcinoma

USMLE Step 1 trap: Overestimates metastatic risk of BCC, failing to distinguish it from SCC's higher metastatic potential. BCC almost never metastasizes despite being locally invasive; SCC has meaningful metastatic potential, especially on the lip and ear.

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two most common skin cancers, and USMLE Step 1 tests them in ways that go well beyond simple identification. You need to know appearance, molecular mechanism, precursor lesions, high-risk sites, and when each lesion actually metastasizes. The exam will hand you a clinical vignette — a pearly nodule with rolled edges on an elderly man's nose, or a hyperkeratotic ulcerated plaque on the lip — and ask you to identify the lesion, predict behavior, or explain the underlying pathway.

The trickiest part is that students routinely conflate the two cancers. BCC looks more dramatic under the microscope (nests of basaloid cells, palisading nuclei) and behaves more indolently — it is locally invasive but almost never metastasizes. SCC looks less exotic but actually carries meaningful metastatic potential, especially at high-risk sites. Students also misplace BCC's molecular driver, lumping it with melanoma's BRAF/RAS story instead of recognizing it as a Hedgehog pathway tumor driven by PTCH1 loss-of-function. Gorlin syndrome (nevoid BCC syndrome) is the syndromic form that reinforces this pathway on the exam.

USMLE Step 1 also tests actinic keratosis not as a throwaway 'benign' diagnosis but as a premalignant SCC precursor requiring active treatment. If you see a vignette describing a rough, scaly plaque on sun-damaged skin in an older patient and you dismiss it as benign, you will miss the management question that follows. Know the management options (5-FU, cryotherapy for actinic keratosis; Mohs surgery for high-risk BCC/SCC) and understand why certain sites — lip, ear — change the metastatic calculus for SCC entirely.

From real student decks
57%have cards covering this topic
35%have mature cards

Common misconceptions

Common mistake
Wrong: Basal cell carcinoma frequently metastasizes like squamous cell carcinoma.
Right: BCC almost never metastasizes despite being locally invasive; SCC has meaningful metastatic potential, especially on the lip and ear.
BCC invades deeply and can destroy local structures (orbits, skull), which makes it feel clinically aggressive — but it almost never enters lymphatics or hematogenous spread. SCC, by contrast, has a meaningful metastatic rate that climbs sharply when the tumor is on the lip or ear. On the exam, if a question asks which lesion metastasizes, the answer is SCC; BCC's danger is local destruction, not distant spread.
Common mistake
Wrong: BCC arises from mutations in the same pathway as melanoma (BRAF/RAS).
Right: BCC arises from constitutive activation of the Hedgehog signaling pathway (PTCH1 loss-of-function mutation), which is the target of vismodegib.
Melanoma is driven by BRAF/RAS/MAP kinase signaling, which is a completely separate pathway from BCC. BCC arises when PTCH1 — the Hedgehog pathway brake — is lost, leading to unrestrained Smoothened (SMO) activity and downstream tumor growth. This distinction matters clinically because vismodegib (SMO inhibitor) is the targeted therapy for advanced BCC, not a BRAF inhibitor.
Common mistake
Wrong: Actinic keratosis is a benign lesion with no malignant potential.
Right: Actinic keratosis is the premalignant precursor to cutaneous SCC and should be treated (e.g., with 5-fluorouracil or cryotherapy).
Actinic keratosis is not a benign incidental finding — it is carcinoma in situ of the epidermis and the direct precursor to invasive cutaneous SCC. Left untreated, a percentage progress to invasive cancer. The exam expects you to know that actinic keratoses should be treated with topical 5-fluorouracil, imiquimod, or cryotherapy, not simply monitored.
Common mistake
Wrong: All cutaneous SCCs carry the same low metastatic risk regardless of location.
Right: SCC on the lip and ear carries significantly higher metastatic risk than SCC on sun-exposed trunk or extremities.
Most cutaneous SCCs on the trunk or extremities have a low metastatic rate (roughly 2-5%), but SCC on the lip carries metastatic rates approaching 10-15%, and SCC on the ear is similarly high-risk. Location is a prognostic variable the exam specifically probes, so when a vignette places SCC on the lip or ear, it is signaling higher metastatic risk and more aggressive management.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Identify BCC from its classic clinical appearance (pearly or translucent nodule with rolled, telangiectatic borders), recognize that it occurs most often on the head and neck, and know that it is locally destructive but almost never metastasizes.
  2. Explain the molecular mechanism driving BCC: loss-of-function mutation in PTCH1 causes constitutive Hedgehog pathway activation, and know that vismodegib (a Hedgehog inhibitor) is the targeted therapy; also recognize Gorlin syndrome as the hereditary form.
  3. Recognize SCC by its appearance (ulcerated, hyperkeratotic, or verrucous plaque), identify actinic keratosis as its direct premalignant precursor, and know that chronic sun exposure on the face, ears, lip, and dorsal hands are the most common sites.
  4. List the risk factors that increase SCC risk (UV radiation, immunosuppression, chronic wounds, arsenic exposure, HPV in anogenital SCC) and understand that SCC carries real metastatic potential — especially on the lip and ear — unlike BCC.
  5. Select appropriate management based on lesion type and site: Mohs micrographic surgery for high-risk or cosmetically sensitive BCC/SCC, standard excision for lower-risk lesions, and topical 5-fluorouracil or cryotherapy for actinic keratosis.

Can you avoid these mistakes?

A 68-year-old man has a 1 cm pearly nodule with rolled edges and central telangiectasias on his nose. What is the diagnosis, and what is the expected metastatic behavior of this lesion?
A patient with Gorlin syndrome develops multiple skin cancers at a young age. What gene is mutated, what pathway does it regulate, and what drug could be used to treat advanced disease?
A 72-year-old woman with years of sun exposure has a rough, erythematous, scaly plaque on her cheek. Biopsy shows atypical keratinocytes confined to the epidermis. What is this lesion, and what is the appropriate treatment?
You are comparing two patients: one with BCC on the nose and one with SCC on the lower lip. Which patient has higher risk of regional lymph node metastasis, and what feature of SCC explains this difference compared to BCC?

Related topics

Bone Cells and Matrix Endochondral vs Membranous Ossification Fracture Healing Stages Compartment Syndrome

See how your Anki deck covers this topic.

Upload your deck for a free audit →